Lindsay Rosenwald - Avenue Therapeutics Executive Director
| ATXIDelisted Stock | USD 0.36 0.02 5.26% |
Director
Lindsay Rosenwald is Executive Director of Avenue Therapeutics
| Age | 70 |
| Phone | 781 652 4500 |
| Web | https://www.avenuetx.com |
Lindsay Rosenwald Latest Insider Activity
Tracking and analyzing the buying and selling activities of Lindsay Rosenwald against Avenue Therapeutics pink sheet is an integral part of due diligence when investing in Avenue Therapeutics. Lindsay Rosenwald insider activity provides valuable insight into whether Avenue Therapeutics is net buyers or sellers over its current business cycle. Note, Avenue Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Avenue Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Lindsay Rosenwald six days ago Acquisition by Lindsay Rosenwald of 8133 shares of Fortress Biotech subject to Rule 16b-3 | ||
Lindsay Rosenwald over two months ago Acquisition by Lindsay Rosenwald of 454153 shares of Fortress Biotech subject to Rule 16b-3 | ||
Lindsay Rosenwald over six months ago Acquisition by Lindsay Rosenwald of 1567515 shares of Fortress Biotech at 1.7 subject to Rule 16b-3 | ||
Lindsay Rosenwald over six months ago Acquisition by Lindsay Rosenwald of 10000 shares of Journey Medical at 3.04 subject to Rule 16b-3 |
Avenue Therapeutics Management Efficiency
The company has return on total asset (ROA) of (4.7194) % which means that it has lost $4.7194 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.351) %, meaning that it created substantial loss on money invested by shareholders. Avenue Therapeutics' management efficiency ratios could be used to measure how well Avenue Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 1 records | DIRECTOR Age | ||
| Mark Ternouth | Virax Biolabs Group | 56 | |
Management Performance
| Return On Equity | -5.35 | ||||
| Return On Asset | -4.72 |
Avenue Therapeutics Leadership Team
Elected by the shareholders, the Avenue Therapeutics' board of directors comprises two types of representatives: Avenue Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Avenue. The board's role is to monitor Avenue Therapeutics' management team and ensure that shareholders' interests are well served. Avenue Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Avenue Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lindsay Rosenwald, Executive Director | ||
| Xiaoqin MD, Consultant | ||
| Alexandra MD, Chief Officer | ||
| Srinivas Subramanian, Executive President | ||
| David Jin, COO CFO |
Avenue Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Avenue Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -5.35 | ||||
| Return On Asset | -4.72 | ||||
| Current Valuation | (1.73 M) | ||||
| Shares Outstanding | 2.05 M | ||||
| Shares Owned By Insiders | 25.23 % | ||||
| Shares Owned By Institutions | 15.32 % | ||||
| Number Of Shares Shorted | 92.16 K | ||||
| Price To Earning | (10.52) X | ||||
| Price To Book | 0.33 X | ||||
| EBITDA | 4.05 M |
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avenue Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Consideration for investing in Avenue Pink Sheet
If you are still planning to invest in Avenue Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Avenue Therapeutics' history and understand the potential risks before investing.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |